Adma Biologics, Inc.
ADMA· Nasdaq
Released Nov 5, 2025, after the close
10-Q filed Nov 5, 2025, 36 days after period end · 0001140361-25-040578
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $134.22M | $119.84M | $67.28M | $41.09M |
| Net Income | $36.43M | $35.91M | $2.57M | -$14.90M |
| EPS Diluted |
Adma Biologics, Inc. · CIK 1368514 · Engraved from SEC EDGAR
| $0.15 |
| $0.15 |
| $0.01 |
| -$0.08 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.